We are live on ! Find out more
RPSM

Royalty Pharma Sub-Manager Portfolio holdings

AUM $242M
This Fund
S&P 500
This Quarter Est. Return
+27.86%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$242M
AUM Growth
+$69.2M
Cap. Flow
+$17.4M
Cap. Flow %
7.18%
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
–
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
KLRA
Kailera Therapeutics
KLRA
+$54M

Top Sells

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$36.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
1
Cytokinetics
CYTK
$10.8B
$83.5M 34.52%
980,392
– –
ZBIO
2
Zenas BioPharma
ZBIO
$2.2B
$60.6M 25.05%
2,388,150
– –
KLRA
3
Kailera Therapeutics
KLRA
$2.3B
$54.1M 22.36%
+2,455,357
New +$54M
BHVN icon
4
Biohaven
BHVN
$2.17B
$43.7M 18.06%
2,936,507
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-3,846,154
Closed -$36.6M

Similar funds

FH
Financial Harvest Winter Park, Florida $242M AUM 23.25% 1-Year Est. Return
SA
Sunesis Advisors Overland Park, Kansas $242M AUM 15.73% 1-Year Est. Return
TFP
TrueWealth Financial Partners Bellevue, Washington $242M AUM 14.39% 1-Year Est. Return
WCP
Wealthcare Capital Partners West Chester, Pennsylvania $242M AUM 18.96% 1-Year Est. Return
UI
Unconventional Investor Portsmouth, New Hampshire $242M AUM 18.7% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $242M AUM 20.33% 1-Year Est. Return
DEA
DoubleLine ETF Adviser Tampa, Florida $242M AUM 7.85% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $242M AUM 17.72% 1-Year Est. Return

Royalty Pharma Sub-Manager's Q2 2026 Portfolio in Review

As of Q2 2026, Royalty Pharma Sub-Manager held 5 positions worth $242M, up 40% from $173M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Royalty Pharma Sub-Manager deployed $17.4M of net new capital in Q2 2026, opening 1 new position. Its largest new stake was Kailera Therapeutics: 2,455,357 shares worth $54.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the most notable exit was BioCryst Pharmaceuticals, an estimated $36.6M sold.

  • Royalty Pharma Sub-Manager's largest Q2 2026 buy was Kailera Therapeutics: 2,455,357 shares worth $54.1M.
  • Royalty Pharma Sub-Manager fully exited BioCryst Pharmaceuticals in Q2 2026, selling an estimated $36.6M.
  • Royalty Pharma Sub-Manager's ten largest holdings make up 100% of its $242M portfolio in Q2 2026.
  • Royalty Pharma Sub-Manager opened 1 new position and closed 1 in Q2 2026.
  • Royalty Pharma Sub-Manager's portfolio value rose 40% quarter-over-quarter to $242M.

Based on Royalty Pharma Sub-Manager's 13F filing for Q2 2026, filed 14 Aug 2026.